Saliva could power medical devices; Medtronic touts stent graft results;

@FierceMedDev: OPKO Health to buy Israeli inhaler developer Inspiro Medical for undisclosed price. News | Follow @FierceMedDev

@VarunSaxena2: Report: Pfizer pitches $101B megamerger to struggling AstraZeneca - FierceBiotech. More from FierceBiotech | Follow @VarunSaxena2

@EmilyWFierce: Wearable data glove that translates motion into sound could mean big things for the American deaf community. Story | Follow @EmilyWFierce

@MichaelGFierce: MIT team delivers three ovarian cancer drugs with one particle. Article from FierceDrugDelivery | Follow @MichaelGFierce

> Researchers at Penn State and Saudi Arabia's King Abdullah University of Science and Technology have developed a fuel cell that derive power from human spit, technology they say could find a home in medical devices. Article (sub. req.)

> Medtronic ($MDT) says its market-leading Endurant stent graft performed well in two real-world observational studies, posting low rates of mortality and reintervention in three- and 5-year data. More

> The FDA is discouraging doctors from using power morcellation to treat uterine fibroids, warning that the procedure can fuel the spread of cancer. News (sub. req.)

Biotech News

@FierceBiotech: Former Creighton professor named chief medical officer at 23andMe. Roundup | Follow @FierceBiotech

@JohnCFierce: I added the top 5 rounds from Q1 in my biotech VC story. And not a one of the biotechs is in the Boston area. Story | Follow @JohnCFierce

@DamianFierce: Here's some NYTimes background on the procedure FDA's warning about (with a remarkably NYTish headline): Article (sub. req.)| Follow @DamianFierce

@EmilyMFierce: New MRSA superbug emerges in Brazilian patient. Story | Follow @EmilyMFierce

> Sarepta rockets up after mapping a shortcut to the FDA with DMD hopeful eteplirsen. Story

> Zafgen tees up an $86M IPO for eye-catching obesity drug. More

> Say what? Pfizer's $101B buyout pitch to AstraZeneca sparks a megadebate. News

Pharma News

@FiercePharma: Top-read story over the long weekend: Gilead's Sovaldi, GSK's Anoro stand out in 2014's blockbuster crop, report says. Story | Follow @FiercePharma

@TracyStaton: Juicy trade-secrets dispute between Bristol-Myers + its ad agency and an account manager who jumped ship. More from MediaPost | Follow @TracyStaton

@EricPFierce: Bill that would have paid drug disposal costs in California out of pharma's pocket left in the recycle bin. Article | Follow @EricPFierce

@CarlyHFierce: Full steam ahead for Copaxone copies as SCOTUS denies Teva's bid for delay. More | Follow @CarlyHFierce

> AbbVie careful about gay rights in its discussion of a new trial. News

> Bulk up or slim down? Maybe both: Pfizer said to weigh a $100B deal for AstraZeneca. Story

> Report: Biopharma CEOs score 'supersalaries' even as sales decline. Article

CRO News

> Certara buys Synchrogenix with its eye on regulatory writing. Story

> InVentiv signs up to get IntelliCell's regenerative drug into the clinic. More

> AMRI plans to shutter an R&D shop to save cash. Article

> Quintiles taps OmniComm for early-stage data management. News

> WuXi poaches an AstraZeneca exec to amp up Chinese R&D. Report

Biotech IT News

> U.K. and Canadian governments back bioinformatics, omics research projects. More

> BlackBerry plans healthcare-focused smartphone after making eClinical investment. Story

> Europe puts data management at the heart of $4B drug innovation drive. Article

> Pfizer, PhRMA and others pick holes in FDA social media guidance. News

> Google adds UCSF geneticist to Calico's roster. Report

Suggested Articles

Tangen Biosciences, developers of cheap and portable molecular diagnostics for outside the lab, has raised $9 million to kick off its VC efforts.

Targeting CA19-9, a biomarker that's been used to assess pancreatic disease burden, may help treat pancreatic cancer, scientists found.

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.